CRISPR Vehicles Break Down Barriers to In Vivo Genome Editing

Charlesworth CT , Deshpande PS , Dever DP , et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med . 2019; 25(2): 249–254.

Chen G , Abdeen AA , Wang Y , et al. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat. Nanotechnol . 2019; 14(10): 974–980.

National Institutes of Health Project Information. Enabling nanoplatforms for targeted in vivo delivery of CRISPR/Cas9 ribonucleoproteins in the brain. Awardee organization: University of Wisconsin– Madison. Project leader: Gong, S. Project number: 1UG3NS111688-01.

Yin H , Song CQ , Dorkin JR , et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol . 2016; 34(3): 328–333.

Huang H-R . CRISPR/Cas9-Mediated Targeted Insertion of Human F9 Achieves Therapeutic Circulating Protein Levels in Mice and Non-Human Primates. Presented at: 22nd Annual Meeting of the American Society of Gene and Cell Therapy. April 29, 2019; Washington, DC.